Syndax Pharmaceuticals (SNDX) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Syndax Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 3 sold $2.7M of SNDX stock on the open market.
Get emailed when insiders cluster-buy stocks like SNDX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SNDX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $785K | 1 |
| Q2 2026 | — | 0 | $1.3M | 4 |
| Q1 2026 | — | 0 | $628K | 4 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Syndax Pharmaceuticals Inc insiders reported open-market purchases totaling $0, while 3 insiders reported sales totaling $2.7M. 3 of 9 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 9SEC | Michael A MetzgerCEO | Sell Plan | 32,375484,843 held (−6%) | $24.24 | $785K | -29.9% | — |
| Jun 12SEC | Nicholas A.j. BotwoodHead Of R&D, Cmo | Sell Plan | 34,28060,885 held (−36%) | $18.00 | $617K | -5.6% | — |
| Jun 12SEC | Nicholas A.j. BotwoodHead Of R&D, Cmo | Sell Plan | 31,23560,885 held (−34%) | $18.14 | $567K | -6.3% | — |
| Jun 2SEC | Michael A MetzgerCEO | Sell | 6,847484,843 held (−1%) | $18.99 | $130K | -10.5% | — |
| Jun 2SEC | Keith A. GoldanCFO | Sell | 1,177139,252 held (−1%) | $18.99 | $22K | -10.5% | — |
| Feb 10SEC | Michael A MetzgerCEO | Sell | 17,159491,690 held (−3%) | $21.03 | $361K | -19.2% | — |
| Feb 10SEC | Keith A. GoldanCFO | Sell | 3,410140,429 held (−2%) | $21.03 | $72K | -19.2% | — |
| Feb 6SEC | Michael A MetzgerCEO | Sell | 7,412508,849 held (−1%) | $20.62 | $153K | -17.6% | — |
| Feb 6SEC | Keith A. GoldanCFO | Sell | 2,082143,839 held (−1%) | $20.62 | $43K | -17.6% | — |
Insiders at Syndax Pharmaceuticals Inc
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Michael A MetzgerCEO | — | $1.4M | Jul 9, 2026 | — |
| Nicholas A.j. BotwoodHead Of R&D, Cmo | — | $1.2M | Jun 12, 2026 | — |
| Keith A. GoldanCFO | — | $137K | Jun 2, 2026 | — |
SNDX stock: common questions
Are Syndax Pharmaceuticals Inc insiders buying SNDX stock?
In the past 12 months, 0 insiders reported open-market purchases of SNDX worth $0.
Are Syndax Pharmaceuticals Inc insiders selling SNDX stock?
3 insiders reported sales worth $2.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SNDX's 52-week range?
Over the past year SNDX has traded between $13.11 and $25.15. It last closed at $16.99 on Oct 9, 2026.